Aptorum Group Limited

[On Demand]
Aptorum Group (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialisation of therapeutic assets to treat diseases with unmet medical needs. In particular, Aptorum Group is currently developing therapeutics in the areas of oncology, infectious diseases and women’s health.

Targeted development milestones for some of the key programs include:

ALS-4 (next-generation anti-infective for Staphylococcus aureus including MRSA via a non-bactericidal antivirulent approach): a new chemical entity (NCE) small molecule drug currently in a Phase 1 clinical trial, targeted for potential administration both on a standalone or a combined basis with other existing antibiotics such as vancomycin;

SACT-1 (neuroblastoma & other solid tumours): a repurposed drug programme with prior human safety and toxicity data available, in preparation to open an IND with US FDA to commence clinical studies in 2021;
NASDAQ, Euronext Paris
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
President and Executive Director
Aptorum Group Ltd.